Prime medicine
Prime Medicine is a biotechnology company focused on providing innovative genetic therapies through advanced gene editing technology known as Prime Editing, which aims to restore normal genetic function and address a wide range of diseases with significant unmet medical needs.
Prime medicine Overview
Prime medicine Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 10/20/2022 | ||||
Series B | 4/20/2021 | ||||
Series A | 9/26/2019 |
Prime medicine Investors
Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
---|---|---|---|---|
ARCH Venture Partners | Series A, Series B | Series A (2019-09-26) | ||
Arrive Opportunities Management | Series A, Series B | Series A (2019-09-26) | ||
F-Prime Capital | Series A, Series B | Series A (2019-09-26) | ||
GV | Series A, Series B | Series A (2019-09-26) | ||
Public Sector Pension Investment Board | Series B | Series B (2021-04-20) |
Prime medicine 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Prime medicine Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Prime medicine News
Prime Medicine lays off workers as it trims pipeline
STATOctober 9, 2024
Prime Medicine shares hold Buy rating amid BMS deal
Investing.comOctober 3, 2024
Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright
MarketBeatOctober 2, 2024
Prime Medicine, Inc. Expected to Earn Q4 2024 Earnings of ($0.28) Per Share (NYSE:PRME)
MarketBeatOctober 2, 2024
BMO maintains Outperform rating on Prime Medicine after BMS partnership
Investing.comOctober 1, 2024
BMO maintains Outperform rating on Prime Medicine after BMS partnership By Investing.com
Investing.com South AfricaOctober 1, 2024
BMO maintains Outperform rating on Prime Medicine after BMS partnership By Investing.com
Investing.com UKOctober 1, 2024
Prime Medicine focuses on key genetic therapy programs By Investing.com
Investing.com South AfricaOctober 1, 2024